Related Experiment Video
Updated: May 24, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Novel therapeutic approaches in pancreatic cancer based on genomic alterations
1Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan. syachida@med.kagawa-u.ac.jp
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which is characterized by invasiveness and dissemination to the lymphatic system and distant organs. In the absence of effective screening methods considerable efforts have thus been made to identify better systemic treatments than gemcitabine, the standard of care for advanced PDAC for well over a decade. However, until now only erlotinib, an epidermal growth-factor receptor tyrosine kinase inhibitor, has demonstrated a modest survival benefit in combination with gemcitabine in a phase III clinical trial. More recently, detailed global genomic analyses have provided a snapshot of the landscape of tumor genomes by showing that they contain four high frequency mutated genes and many low frequency mutated genes that correspond to 12 core signaling pathways. Strategies to target these frequently altered genes and their pathways, or low frequency mutated genes corresponding to the "personalized genome", offer novel therapeutic strategies. In the near future, the complete sequencing of the coding genome, together with the dramatically reduced costs of whole genome sequencing, will provide new opportunities to treat PDAC.
Insights
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer. Genomic analysis reveals new therapeutic targets, offering hope for improved treatments beyond current standards like gemcitabine.
Area of Science:
- Oncology
- Genomics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis.
- Current systemic treatments for advanced PDAC, primarily gemcitabine, offer limited efficacy.
- Novel therapeutic strategies are urgently needed to improve patient survival.
Purpose of the Study:
- To review the current landscape of systemic treatments for advanced PDAC.
- To explore the potential of novel therapeutic strategies informed by genomic analyses.
- To highlight the future opportunities in PDAC treatment through advanced sequencing.
Main Methods:
- Review of existing clinical trial data for PDAC systemic treatments.
- Analysis of recent global genomic studies in PDAC.
- Discussion of targeted therapy and personalized medicine approaches.
Main Results:
- Gemcitabine remains the standard of care, with limited benefit from erlotinib combination therapy.
- Genomic analyses identified four frequently mutated genes and 12 core signaling pathways in PDAC.
- Targeting these genomic alterations presents promising therapeutic avenues.
Conclusions:
- Genomic insights are revolutionizing the understanding and treatment of PDAC.
- Targeted therapies and personalized medicine hold significant potential for future PDAC treatment.
- Advancements in whole genome sequencing will accelerate the development of new PDAC therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Pharmacogenomics: Identification of New Drug Targets